KEAP1 and metabolic disease: Numerous studies have demonstrated therapeutic benefit of KEAP1-targeting compounds in multiple experimental models of chronic disease, including respiratory, gastrointestinal, cardiovascular, neurodegenerative, autoimmune, and metabolic diseases.